Regulatory Affairs Services Provider in Greece
Greece operates within one of the most tightly regulated pharmaceutical environments in Europe, where market access is not limited by approval alone but shaped by pricing controls, reimbursement eligibility, and ongoing compliance obligations. While alignment with the European Union framework creates predictability, execution challenges arise at the national level, particularly in pricing negotiations, HTA-linked decisions, and post-approval requirements.
For companies entering Greece, regulatory success depends on more than selecting the correct EU pathway. It requires dossier precision, alignment with national expectations, and a clear strategy for transitioning from authorization to reimbursement.
DDReg delivers Regulatory Affairs Services in Greece with a focus on execution, supporting pharmaceutical companies across submission planning, approval, and lifecycle compliance within both EU and national systems.
Drug Regulatory Authority Framework in Greece
Pharmaceutical regulation in Greece is governed by the National Organization for Medicines (EOF), the competent authority responsible for oversight of medicinal products and healthcare compliance.
EOF operates within the European regulatory framework and collaborates closely with the European Medicines Agency (EMA). Its core responsibilities include:
- Evaluation of medicinal products through national procedures
- Participation in centralized, decentralized, and mutual recognition procedures
- Pharmacovigilance oversight and signal management
- Clinical trial authorization and supervision
- Inspection of manufacturing, distribution, and GDP/GMP compliance
- Control of labeling, advertising, and promotional materials
While EU legislation defines the approval framework, EOF enforces national requirements that directly impact timelines and market access.
Regulatory Affairs Services in Greece
DDReg provides Pharmaceutical Regulatory Affairs in Greece with a clear focus on submission quality, regulatory alignment, and lifecycle continuity.
Our services include:
- Regulatory strategy and EU pathway selection (CP, DCP, MRP, national)
- Marketing authorization support across EU and national procedures
- CTD/eCTD dossier preparation, publishing, and technical validation
- Dossier gap analysis aligned with EMA and EOF expectations
- Submission planning, tracking, and authority coordination
- Regulatory query response management with structured documentation
- Pricing and reimbursement support aligned with Greek HTA and pricing systems
- MAH support and local regulatory coordination within the EU
- Lifecycle management including variations, renewals, and safety updates
- Labeling and artwork compliance (EU QRD templates + national requirements)
- Ongoing regulatory intelligence and policy monitoring
Each engagement is structured to reduce review cycles, minimize queries, and maintain compliance beyond approval.
Regulatory Affairs Process in Greece
Pharmaceutical approval in Greece is governed by EU regulatory pathways, but national processes determine final market access.
Products may be authorized through:
- Centralized Procedure (CP) via EMA, granting EU-wide approval
- Decentralized Procedure (DCP) for products not yet approved in the EU
- Mutual Recognition Procedure (MRP) for extending existing EU approvals
- National Procedure, where applicable
All submissions must follow eCTD format, with Module 1 localized for Greece.
Following marketing authorization, companies must navigate:
- Pricing approval, based on external reference pricing systems
- Reimbursement evaluation, often linked to health technology assessment (HTA) criteria
- Clawback and rebate frameworks, which directly impact commercial viability
Delays are often not due to approval timelines, but due to misalignment between regulatory approval and pricing/reimbursement readiness.
Why Choose DDReg for Regulatory Affairs Services in Greece
DDReg approaches Regulatory Affairs Consulting in Greece with a focus on execution detail and regulatory risk management, not generic advisory.
- Direct experience with EU procedures and EOF-specific expectations
- Strong control over eCTD compliance, validation, and submission readiness
- Integrated regulatory + pricing awareness to support market access planning
- Structured handling of authority queries to reduce review delays
- Lifecycle management systems aligned with EU variation frameworks
This ensures consistent progress from regulatory planning to approval and lifecycle management.
Global Reach Explorer
Find Your Solution
Our Regulatory Affairs Consulting Services in Greece portfolio covers:
Regulatory Strategies
The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...
New Product Marketing Authorizations
Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...
Gap Analysis and Remediation
In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...
Regulatory Due Diligence
Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...
API & DMF services
Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...
CMC Advisory
DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...
Post Approval Life Cycle Management
Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...
Certification Services
Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...
ANDA and MA Holder Services
Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.
Publishing & Submission
Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...
